Patents Assigned to Glaxo Group Limited
  • Patent number: 10808029
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • Patent number: 10808040
    Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Mary Birchler, Rudolf M. T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • Publication number: 20200315919
    Abstract: A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy} hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11ß,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 8, 2020
    Applicant: Glaxo Group Limited
    Inventors: Osama Ahmed ASWANIA, Zhong JIANG, Trevor Charles ROCHE, Mark WHITAKER
  • Patent number: 10703814
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 7, 2020
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • Publication number: 20200171009
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Applicant: Glaxo Group Limited
    Inventors: Darrell BAKER, Mark BRUCE, Glenn CRATER, Brian NOGA, Marian THOMAS, Patrick WIRE
  • Patent number: 10633673
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 28, 2020
    Assignee: GLAXO GROUP LIMITED
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Patent number: 10624898
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: April 21, 2020
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Patent number: 10548827
    Abstract: The invention relates to non-aqueous dentrfrice compositions comprising a surfactant system. The surfactant system consists of a combination of surfactants i.e. a betaine and a taurate surfactant; or a betaine and an alkyl sulphate surfactant; or a betaine, a taurate and an alkyl sulphate surfactant.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: February 4, 2020
    Assignee: Glaxo Group Limited
    Inventor: John Hodgkinson
  • Patent number: 10466252
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Patent number: 10383879
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 20, 2019
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Patent number: 10302655
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Patent number: 10294214
    Abstract: Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: May 21, 2019
    Assignees: Vanderbilt University, King's College London, Glaxo Group Limited
    Inventors: Roger D. Cone, Michael J. Bishop, Eugene L. Stewart, Lawrence A. Wolfe, Jaques Pantel, Julien Sebag, C. David Weaver, Savannah Williams, Helen Cox, Iain Tough, Luis Diaz Gimenez, Subramanian Baskaran
  • Patent number: 10221234
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Tejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Patent number: 10174053
    Abstract: The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 8, 2019
    Assignees: Glaxo Group Limited, Shionogi and Co., Ltd.
    Inventors: Toshiaki Aoki, Hiroki Kusano, Xiangmin Liao, Neil David Pearson, Israil Pendrak, Jun Sato, Reema K. Thalji, Kenji Yamawaki, Katsuki Yokoo
  • Patent number: 10039755
    Abstract: Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: August 7, 2018
    Assignee: Glaxo Group Limited
    Inventors: Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Robert John Sheppard, Ann Louise Walker, Christopher Wellaway, David Matthew Wilson
  • Publication number: 20180207172
    Abstract: A method of treating vitiligo, including prophylaxis, in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a compound of Formula (I): wherein: X is CR1 or N; Y is CH, C or N; R1 is hydrogen, C1-6alkoxy or C1-6alkyl; R2 is hydrogen, C1-6alkoxy, halo, —C(O)C1-6alkyl, CN, halo-C1-6alkyl or —C(O)NR4R5; R3 is hydrogen or C1-6alkoxy; R4 is hydrogen or C1-6alkyl: R5 is hydrogen or C1-6alkyl; and m and n are integers each independently selected from 1 and 2, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 21, 2016
    Publication date: July 26, 2018
    Applicant: Glaxo Group Limited
    Inventors: Marion Catherine DICKSON, David RUBENSTEIN
  • Patent number: 10004633
    Abstract: A dispenser for the delivery of a droplet of a liquid comprises a housing which defines an outlet orifice, a tip seal, biased against the housing to seal the outlet orifice, and a dosing pump for pumping a liquid to the outlet nozzle. The dispenser further comprises an actuation pump configured to provide a hydraulic opening force to the tip seal for opening of the outlet orifice. Preferably the actuation pump is configured to operate at a higher pressure than the dosing pump.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 26, 2018
    Assignee: Glaxo Group Limited
    Inventors: David Blakey, Gary Thomas Crosby
  • Patent number: 10005731
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: June 26, 2018
    Assignee: Glaxo Group Limited
    Inventors: Fangbin Han, Hui Lei, Xichen Lin, Qinghua Meng, Yonghui Wang
  • Patent number: D814019
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: March 27, 2018
    Assignee: Glaxo Group Limited
    Inventors: Gary Thomas Crosby, John Deamer, Philip William Farr, Stephen Maurice Pitson, Alan Anthony Wilson
  • Patent number: D841740
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: February 26, 2019
    Assignee: Glaxo Group Limited
    Inventors: William Bull, Richard Adams, Philippe Ragot, Carlo Brunelli, Lisa Olivieri, Jeffrey Schons, Alec Johnson